Xeris targets over 30% revenue growth in 2026 while expanding Recorlev investment and advancing XP-8121
Source: SeekingAlpha
2026-03-02 10:58:36 ET
More on Xeris Pharmaceuticals
- Xeris Biopharma Holdings, Inc. (XERS) Q4 2025 Earnings Call Transcript
- Xeris Biopharma: Strong Recorlev Momentum And Pipeline Opportunity
- Xeris Biopharma: A Balanced Perspective Needed (Rating Downgrade)
- Xeris Biopharma expects full-year 2025 revenue above estimates
- Seeking Alpha’s Quant Rating on Xeris Pharmaceuticals
Read the full article on Seeking Alpha
For further details see:
Xeris targets over 30% revenue growth in 2026 while expanding Recorlev investment and advancing XP-8121
Xeris Pharmaceuticals Inc.
NASDAQ: XERS
XERS Trading
0.7% G/L:
$5.78 Last:
773,597 Volume:
$5.60 Open:
XERS Latest News
XERS Stock Data
$1,185,529,045
155,188,988
4.48%
76
N/A
Biotechnology & Life Sciences
Healthcare
US
Chicago
